Dedifferentiation in the metastatic progression of prostate carcinoma

Liang Cheng, Jeff Slezak, Erik J. Bergstralh, John C. Cheville, Susan Sweat, Horst Zincke, David G. Bostwick

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

BACKGROUND. Dedifferentiation is a distinctive feature of cancer progression. Detailed histologic analysis of primary prostate carcinoma and synchronous lymph node metastases may improve our understanding of the complex process of cancer progression and metastasis. METHODS. The authors studied 242 regional lymph node positive prostate carcinoma patients who underwent radical prostatectomy and bilateral lymphadenectomy between 1987 and 1992 at the Mayo Clinic. Patients ranged in age from 47-79 years (median, 66 years). The median follow-up was 6.1 years. Gleason scores of lymph node metastases and primary tumors were compared and correlated with systemic disease progression. Histologic dedifferentiation was defined as a higher Gleason grade in the lymph node metastases than in the primary tumor. Systemic disease progression was defined as the presence of distant metastases documented by biopsies, abdominal computed tomography, plain radiograph, or bone scan. RESULTS. The 5-year systemic progression free survival (PFS) rate was 90%. The Gleason score in the lymph node metastases was higher than in the primary tumor in 45% of patients, lower in 12% of patients, and matched exactly in 43% of patients. The 5-year PFS was significantly different between patients with histologic dedifferentiation (88% ± 3) and those without dedifferentiation (94% ± 2) (P = 0.04). Adjusting for the Gleason grade of the primary tumor and total lymph node tumor volume, the relative risk for disease progression associated with dedifferentiation was 1.8 (95% confidence interval, 0.7-4.7; P = 0.25). CONCLUSIONS. The findings of the current study demonstrate the morphologic heterogeneity of metastases from prostate carcinoma. There is a trend toward histologic dedifferentiation when prostate carcinoma metastasizes to regional lymph nodes. This dedifferentiation, although univariately significant, was not associated with disease progression when adjusted for lymph node tumor volume.

Original languageEnglish (US)
Pages (from-to)657-663
Number of pages7
JournalCancer
Volume86
Issue number4
DOIs
StatePublished - Aug 15 1999

Keywords

  • Dedifferentiation
  • Metastasis
  • Progression
  • Prostate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Dedifferentiation in the metastatic progression of prostate carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Cheng, L., Slezak, J., Bergstralh, E. J., Cheville, J. C., Sweat, S., Zincke, H., & Bostwick, D. G. (1999). Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer, 86(4), 657-663. https://doi.org/10.1002/(SICI)1097-0142(19990815)86:4<657::AID-CNCR15>3.0.CO;2-9